Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05636124
Other study ID # STUDY-22-01480
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2, 2023
Est. completion date July 2025

Study information

Verified date December 2023
Source Icahn School of Medicine at Mount Sinai
Contact Sydney Edwards
Phone 212 241 2524
Email sydney.edwards@mountsinai.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, prospective, propensity matched twin armed study conducted on 50 patients in the experimental arm followed for 18 months after intervention evaluating cost effectiveness, safety and efficacy of therapy.


Description:

Although coiling has become the most common form of treatment for intracranial aneurysms, there is evidence to suggest that the cost of coiling is on average 50% greater than the cost of clipping. Device costs represent the majority of this increased financial burden. This issue has only increased over time, as supplies and devices accounted for 24% of the increase in hospital costs per discharge from 2001 to 2006. The list price of coils on the US market ranges from $500 to $3000, thus small changes in the number of coils used per case can result in a large cost saving. The Kaneka iED coil is priced within this normal range, but offers a multi-diameter design that may reduce the number of coils required to achieve adequate embolization. Aside from potential cost savings across all aneurysm types, the ability of the Kaneka iED to both frame and fill with a single coil may prove particularly effective in the treatment of wide-necked aneurysms. In these cases, a wide neck at the base of the aneurysm increased the risk for protrusion of the coil mass back into the normal lumen of the vessel, which can result in stroke and other severe complications. Adjunctive devices such as balloon and stents are often employed to reconstruct the aneurysm neck in these cases, and larger coil mass provided by the Kaneka iED may additionally serve to decrease the risk of coil protrusion.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria: - Patient presenting with ruptured or unruptured cerebral aneurysm appropriate for endovascular treatment as determined by the neuroendovascular treating team - Wide neck side wall or bifurcation intracranial aneurysms (neck > or = to 4 mm or dome-to-neck ratio < 2) within the anterior or posterior circulation - The neurointerventionist feels that the aneurysm can be safely treated using endovascular techniques (direct or assisted coiling) - Patients are 18-80 years of age (inclusive) - Patient must be Hunt and Hess grade 0 to 3 - Patient has given fully informed consent to endovascular coiling procedure. If the patient cannot consent for themselves, appropriate written consent has been sought from their next of kin or appropriate power of attorney. - Aneurysm 6-14 mm in diameter - Patient is willing and able to return for clinical evaluation and follow-up imaging evaluation (angiography) at 3-6 months and 12-18 months after endovascular treatment - The patient has not been previously enrolled in this trial or another related ongoing trial - The aneurysm has not been previously treated by coiling or clipping Exclusion criteria: - Patient has more than one aneurysm requiring treatment in the current treatment session, and only one of those to be treated aneurysms fits the Kaneka inclusion criteria (i.e., - if either (1) a patient has multiple aneurysms, but only one will be treated at enrollment; or (2) if two or more aneurysms are treated during the current treatment session and BOTH are able to be enrolled, then they remain eligible for the trial). Non-treated additional aneurysms may be treated at a later date with any coil type that the operator chooses). - Target aneurysm has had previous coil treatment or has been surgically clipped - Hunt and Hess score is 4 or 5 after subarachnoid hemorrhage - Inability to obtain informed consent - Medical or surgical comorbidity such that the patient's life expectancy is less than 2 years

Study Design


Intervention

Device:
Kaneka i-ED coil
The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.

Locations

Country Name City State
United States Sutter Health Danville California
United States Prisma Health Greenville South Carolina
United States Icahn School of Medicine at Mount Sinai New York New York
United States University of South Florida Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai Kaneka Corporation

Country where clinical trial is conducted

United States, 

References & Publications (3)

Bairstow P, Dodgson A, Linto J, Khangure M. Comparison of cost and outcome of endovascular and neurosurgical procedures in the treatment of ruptured intracranial aneurysms. Australas Radiol. 2002 Sep;46(3):249-51. doi: 10.1046/j.1440-1673.2002.01053.x. — View Citation

Gandhoke GS, Pandya YK, Jadhav AP, Jovin T, Friedlander RM, Smith KJ, Jankowitz BT. Cost of coils for intracranial aneurysms: clinical decision analysis for implementation of a capitation model. J Neurosurg. 2018 Jun;128(6):1792-1798. doi: 10.3171/2017.3.JNS163149. Epub 2017 Aug 25. — View Citation

Maeda JL, Raetzman SO, Friedman BS. What hospital inpatient services contributed the most to the 2001-2006 growth in the cost per case? Health Serv Res. 2012 Oct;47(5):1814-35. doi: 10.1111/j.1475-6773.2012.01460.x. Epub 2012 Sep 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with Modified Raymond Roy 1-2 Occlusion classification without retreatment Modified Raymond Roy 1-2 occlusion at 18 months without retreatment. The Raymond-Roy Occlusion Classification has 3 responses, where Grade 1 is complete occlusion, no flow of contrast seen in the sac, Grade 2 is partial occlusion, some flow in the neck or sac, and Grade 3 is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome. at 18 months
Primary Number of coils used Number of coils used to assess treatment-related cost effectiveness at treatment and over the course of follow-up to 18 months. up to 18 months post-treatment
Primary Packing density of coils Packing density of coils used to assess treatment-related cost effectiveness at treatment and over the course of follow-up to 18 months. up to 18 months post-treatment
Primary Number of device related serious adverse events Intra and peri-procedural (0-24 hours) device related serious adverse event rate. up to 24 hours
Primary Number of device related serious adverse events Intra and peri-procedural (24 hours to 30 days) device related serious adverse event rate. 24 hours to 30 days
Secondary Rate of complete or near complete aneurysm occlusion without retreatment Rate of complete or near complete aneurysm occlusion without retreatment at 6 months at 6 months
Secondary Number of patients with Modified Raymond-Roy classification 1 The Raymond-Roy Occlusion Classification has 3 responses, where Grade 1 is complete occlusion, no flow of contrast seen in the sac, Grade 2 is partial occlusion, some flow in the neck or sac, and Grade 3 is incomplete occlusion, apparent flow into the sac. Grade 1 indicates the best outcome. at 18 months
Secondary Number of patients who suffer a Major ipsilateral stroke or neurological death Number of patients who suffer a Major ipsilateral stroke or neurological death. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause. at 6 months
Secondary Number of patients who suffer a Major ipsilateral stroke or neurological death Number of patients who suffer a Major ipsilateral stroke or neurological death. A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurologic death is defined as a death which has been adjudicated by the independent clinical events committee to have directly resulted from a neurologic cause. at 18 months
Secondary Changes in Modified Rankin Scale (mRS) score The mRS ranges from 0 to 6, with higher scores indicating a greater degree of disability or dependence. Scores will be assigned based on the following:
0 - no symptoms, 1 - no significant disability, able to carry out all usual activities despite some symptoms, 2 - slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 - moderate disability, requires some help, but able to walk unassisted, 4 - moderately severe disability, unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 - severe disability, requires constant nursing care and attention, bedridden, incontinent, 6 - deceased.
Changes in the mRS score will be assessed between day 30, 6 months, and 12-18 months.
Day 30, 6 months, and 12-18 months
Secondary Changes in National Institutes of Health Stroke Scale (NIHSS) score The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The total NIHSS score can range from 0 to 42, with 0 indicating no stroke symptoms and 42 indicating extremely severe stroke symptoms. So, a higher NIHSS score indicates a greater degree of impairment. Changes in the NIHSS score will be assessed between day 30, 6 months, and 12-18 months. Day 30, 6 months, and 12-18 months
Secondary Ratio of packing density to number of coils used This ratio indicates how many coils were needed to sufficiently pack the aneurysm. A higher ratio of packing density to number of coils used indicates that fewer coils were needed to sufficiently pack the aneurysm. Treatment, day 1
Secondary Raymond-Roy occlusion classification (RROC) Change in the post-coiling appearance of the aneurysm as measured by the Raymond-Roy occlusion classification (RROC) which is an angiographic classification scheme for grading the occlusion of endovascularly treated aneurysms.
class I: complete obliteration class II: residual neck class III: residual aneurysm
Post-procedure to 18 months
Secondary Change in Occlusion outcome status Occlusion outcome status may be designated as stable, improved or worse. baseline and 18 months
Secondary Aneurysm recurrence/coil compaction Aneurysm recurrence/coil compaction is based on whether the coil has been able to stem blood flow. If coil compaction occurs, the aneurysm may recur. Response will be yes/no. Post-procedure to 18 months
Secondary Rate of re-treatment or hemorrhage at 6 months
Secondary Rate of re-treatment or hemorrhage at 18 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02879175 - Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms
Completed NCT01139892 - The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES)
Recruiting NCT06411418 - Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm N/A
Completed NCT02312856 - Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction N/A
Recruiting NCT01054391 - Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae N/A
Completed NCT02657772 - Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms
Completed NCT01465841 - Study of the Penumbra Coil 400 System to Treat Aneurysm N/A
Enrolling by invitation NCT05453240 - Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the LVIS Device
Completed NCT03550638 - Coil System(Ton-bridgeMT) for Endovascular Embolization of Cranial Aneurysms N/A
Terminated NCT02122133 - CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400
Completed NCT01541254 - Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device Phase 2/Phase 3
Terminated NCT01320306 - Intracranial Aneurysms and Cognitive Function
Recruiting NCT01084681 - Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques N/A
Completed NCT00396981 - MAPS Trial: Matrix And Platinum Science Phase 4
Completed NCT02921711 - TRAIL: Treatment of Intracranial Aneurysms With LVIS® System
Recruiting NCT01031147 - Contrast-free Magnetic Resonance Angiography (MRA) at 3.0 T for Intracranial Aneurysm Detection N/A
Completed NCT02921698 - Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment
Completed NCT01801007 - Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms N/A
Completed NCT01793792 - Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support) N/A
Terminated NCT01974700 - Seizure Prophylaxis in Aneurysm Repair Phase 4